9 results about "Incretin" patented technology

The present invention provides a method for treating obesity or an obesity-related disease or disorder, comprising administering a PYY analog in combination with an incretin, wherein the patient's insulin sensitivity is improved with treatment.

Orally administered pharmaceutical compositions comprising incretin or its analogues or derivatives are presented, which allow for prolonged glycemic control. The formulations presented herein incorporate a self-emulsifying drug delivery system (SEDDS). Advantageously, such formulations provide protection in the upper gastrointestinal tract from proteolytic conditions while allowing for efficient drug release and absorption in the lower gastrointestinal tract.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

Compositions are provided that include an incretin analog having activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors (i.e., avian receptor agonists) and one or more additional agents, such as a tonicity agent and a preservative. Methods are also provided for treating diseases, such as type 2 diabetes, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and obesity, with the compositions.

This disclosure provides GLP-1 / GIP and GLP-1 / GCG dual receptor agonists comprising incretin analog polypeptides, as well as their use in the treatment or prevention of type 2 diabetes mellitus (T2DM), hyperlipidemia / dyslipidemia, metabolic syndrome, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risk, and / or obesity.

A method for improving the solubility of a pharmaceutical compound is disclosed, wherein the pharmaceutical compound is insulin, a natural insulin variant, an insulin variant or insulin analog, a GLP-1 agonist, a GIP agonist, a glucagon agonist, an amylin agonist or an incretin mimic. The method involves using a non-nutritive sugar, such as raspberry glycoside, neohesperidin A, dulcitin B, dodecyl-β-D-maltodextrin (DDM), or carhariside, or any combination thereof, in the presence of a solvent such as ethanol or a mixture thereof, followed by removal of the solvent by drying and re-solubilization to generate a water-soluble complex. The complex formed using the disclosed method is also described.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

Provided herein are combination therapies involving an AMPK activator, including compounds that are dual AMPK activators and mitochondrial uncouplers, dosed in combination with incretin-based therapies.